The stock of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) is a huge mover today! About 229,572 shares traded hands. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has declined 4.86% since March 7, 2016 and is downtrending. It has underperformed by 12.45% the S&P500.
The move comes after 7 months positive chart setup for the $2.10 billion company. It was reported on Oct, 10 by Barchart.com. We have $140.37 PT which if reached, will make NASDAQ:LGND worth $798.00 million more.
Analysts await Ligand Pharmaceuticals Inc. (NASDAQ:LGND) to report earnings on November, 14. They expect $0.75 EPS, up 78.57% or $0.33 from last year’s $0.42 per share. LGND’s profit will be $15.48 million for 33.91 P/E if the $0.75 EPS becomes a reality. After $0.17 actual EPS reported by Ligand Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 341.18% EPS growth.
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Ratings Coverage
Out of 5 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 4 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 80% are positive. Ligand Pharmaceuticals has been the topic of 12 analyst reports since September 3, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Roth Capital on Wednesday, September 30. TH Capital maintained the stock with “Buy” rating in Thursday, November 19 report. Roth Capital maintained Ligand Pharmaceuticals Inc. (NASDAQ:LGND) on Monday, September 21 with “Buy” rating. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, October 5. The rating was downgraded by Deutsche Bank to “Sell” on Friday, August 5. The stock of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has “Buy” rating given on Thursday, November 19 by Roth Capital. The firm has “Buy” rating by Roth Capital given on Friday, March 11. The firm earned “Buy” rating on Thursday, September 3 by Roth Capital. The stock of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) earned “Buy” rating by Roth Capital on Friday, December 18. The company was initiated on Wednesday, April 13 by Stephens.
According to Zacks Investment Research, “Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men’s and women’s hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand’s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to intracellular receptors.”
Insitutional Activity: The institutional sentiment decreased to 1.26 in Q2 2016. Its down 0.38, from 1.64 in 2016Q1. The ratio turned negative, as 27 funds sold all Ligand Pharmaceuticals Inc. shares owned while 81 reduced positions. 38 funds bought stakes while 98 increased positions. They now own 22.63 million shares or 4.24% less from 23.63 million shares in 2016Q1.
Columbia Prtn L L C Invest Mgmt, a Maryland-based fund reported 44,756 shares. Aqr Capital Lc holds 0.01% or 29,013 shares in its portfolio. State Street holds 737,003 shares or 0.01% of its portfolio. Wolverine Asset Ltd Com accumulated 0% or 178 shares. First Tru Advsr Ltd Partnership holds 16,865 shares or 0.01% of its portfolio. Redwood Limited Liability holds 0.32% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 29,444 shares. Commonwealth Equity Svcs holds 0% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 4,270 shares. Matarin Cap Mgmt Lc last reported 0% of its portfolio in the stock. Stephens Mngmt Group Llc has invested 1.4% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Court Place Ltd Liability Company last reported 1.44% of its portfolio in the stock. Stifel Fincl holds 0% or 2,159 shares in its portfolio. Goldman Sachs Grp Inc reported 30,989 shares or 0% of all its holdings. Financial Bank Of America De holds 0.01% or 303,080 shares in its portfolio. Fortaleza Asset Mngmt accumulated 0.14% or 1,445 shares. Bb&T holds 0.01% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 2,525 shares.
Insider Transactions: Since May 2, 2016, the stock had 0 insider purchases, and 10 insider sales for $8.29 million net activity. 3,000 shares were sold by HIGGINS JOHN L, worth $352,020 on Thursday, September 22. 1,000 shares were sold by KOZARICH JOHN W, worth $137,569. Aryeh Jason sold $2.98 million worth of stock. $2.72 million worth of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) was sold by Berkman Charles S. $1.53 million worth of shares were sold by FOEHR MATTHEW W on Friday, August 5. Herman Melanie J sold $40,247 worth of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) on Wednesday, May 18.
More important recent Ligand Pharmaceuticals Inc. (NASDAQ:LGND) news were published by: Fool.com which released: “Here’s Why Ligand Pharmaceuticals Inc Is Plunging Today” on September 27, 2016, also Fool.com published article titled: “Licensing Agreements Drive Ligand Pharmaceuticals Inc. 13% Higher in July”, Businesswire.com published: “Ligand to Acquire OMT, Inc., a Leader in Human Antibody Generation, for $178 …” on December 17, 2015. More interesting news about Ligand Pharmaceuticals Inc. (NASDAQ:LGND) was released by: Schaeffersresearch.com and their article: “Analyst Update: Applied Optoelectronics Inc, Ligand Pharmaceuticals Inc., and …” with publication date: September 07, 2016.
LGND Company Profile
Ligand Pharmaceuticals Incorporated (Ligand), incorporated on September 28, 1987, is a biopharmaceutical firm that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Firm employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others. The Company’s partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. The Firm is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.